FINALISTS 2022

SCRIP AWARDS 2022

30 NOVEMBER 2022 · ROYAL LANCASTER, LONDON

Best New Drug Award

Launching innovative new products is the most important function of the industry and a successful new drug launch marks the culmination of years of risky and expensive R&D. This award recognises excellence in pharmaceutical development.

SPONSORED BY wcg™

Agios Pharmaceuticals' Pyrukynd for pyruvate kinase deficiency

In February, Agios launched Pyrukynd (mitapivat), a first-in-class medication and the only targeted treatment for pyruvate kinase deficiency, a rare, lifelong, debilitating blood disease. Supported by a no-cost genetic testing and counseling program that detects over 50 genes related to dozens of disorders that cause chronic anemias, the launch campaign is consistently performing over two times above industry standards for social and digital engagement.

Argenx's Vyvgart for generalized myasthenia gravis

Argenx's Vyvgart (efgartigimod alfa) is a first-of-its-class medicine that is filling an unmet clinical need for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, approximately 85% of patients. Approved by the US FDA in December 2021, it has been rapidly adopted by patients and has the potential to treat over 100 other autoimmune diseases mediated by the same antibody as gMG.

Immunocore's Kimmtrak (tebentafusp) for metastatic uveal melanoma

Kimmtrak is the first approved treatment for patients with unresectable or metastatic uveal melanoma and the first T-cell receptor (TCR) therapeutic to receive regulatory approval. The novel bispecific protein comprised of a soluble TCR fused to an anti-CD3 immune-effector function specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. An off-the-shelf advanced therapy, Kimmtrak represents a paradigm shift in treatment for this aggressive form of cancer.

Legend Biotech/Janssen Biotech's Carvykti for multiple myeloma

Carvykti (ciltacabtagene autoleucel) is a CAR-T therapy with two B-cell maturation antigen-targeting single domain antibodies approved by the US FDA for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. Most patients relapse after undergoing initial treatment and face poor prognoses after treatment with three major drug classes.

Mirum Pharmaceuticals' Livmarli for cholestatic pruritus in patients with Alagille syndrome

Mirum Pharmaceuticals' Livmarli (maralixibat) oral solution was approved in the US in September 2021 for cholestatic pruritus in patients with Alagille syndrome one year of age and older. The oral ileal bile acid transporter inhibitor has been filed for EU approval for the treatment of cholestatic liver disease in patients with Alagille syndrome and is in clinical trials for pediatric liver diseases including progressive familial intrahepatic cholestasis and biliary atresia.

Servier Pharmaceuticals' Tibsovo (ivosidenib tablets) for cholangiocarcinoma with an IDH1 mutation

In August 2021, the US FDA approved Tibsovo (ivosidenib tablets) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) with an IDH1 mutation as detected by an FDA-approved test. With this approval, Tibsovo became the first targeted therapy available for patients with previously treated IDH1-mutated CCA – a rare, aggressive cancer of the bile ducts within and outside of the liver.

Winners are announced at the Awards ceremony and dinner on Wednesday 30th November at the Royal Lancaster Hotel, London.